Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models

Freitag, Tobias; Fagerlund, Riku; Karam, Nihay Laham; Leppänen, Veli-Matti; Uğurlu, Hasan; Kant, Ravi; Mäkinen, Petri; Tawfek, Ahmed; Kumar, Sawan; Strandin, Tomas; Leskinen, Katarzyna; Hepojoki, Jussi; Kesti, Tapio; Kareinen, Lauri; Kuivanen, Suvi; Koivulehto, Emma; Sormunen, Aino; Laidinen, Svetlana; Khattab, Ayman; Saavalainen, Päivi; Meri, Seppo; Kipar, Anja; Sironen, Tarja; Vapalahti, Olli; Alitalo, Kari; Ylä‐Herttuala, Seppo; Saksela, Kalle

doi:10.1016/j.vaccine.2023.04.020

Cited by 6 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NAbs were analyzed with PNAbA described earlier 10,12,13 (University of Helsinki) and two commercial surrogate immunoassays: SARS‐CoV‐2 NeutraLISA (EIM) and cPass TM SARS‐CoV‐2 Neutralization Antibody Detection Kit (GenScript). Both commercial surrogate assays were carried out and interpreted according to the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays

Virtanen,

Korhonen,

Salonen

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

We studied the development of the severe acute respiratory syndrome‐related coronavirus (SARS‐CoV‐2) pandemic in southern Finland in 2020 and evaluated the performance of two surrogate immunoassays for the detection of neutralizing antibodies (NAbs). The data set consisted of 12 000 retrospectively collected samples from pregnant women in their first trimester throughout 2020. All the samples were initially screened for immunoglobulin G (IgG) with SARS‐CoV‐2 spike antibody assay (EIM‐S1, Euroimmun) followed by confirmation with nucleocapsid antibody assay (Architect SARS‐CoV‐2, Abbott). Samples that were reactive (positive or borderline) with both assays were subjected to testing with commercial surrogate immunoassays of NeutraLISA (EIM) and cPassTM (GenScript Biotech Corporation) by using pseudoneutralization assay (PNAbA) as a golden standard. No seropositive cases were detected between January and March. Between April and December, IgG (EIM‐S1 and Abbott positive) and NAb (PNAbA positive) seroprevalences were between 0.4% and 1.4%. NeutraLISA showed 90% and cPass 55% concordant results with PNAbA among PNAbA negative samples and 49% and 92% among PNAbA positive samples giving NeutraLISA better specificity but lower sensitivity than cPass. To conclude, seroprevalence in pregnant women reflected that of the general population but the variability of the performance of serological protocols needs to be taken into account in inter‐study comparison.

show abstract

Section: Methodsmentioning

confidence: 99%

SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays

Virtanen,

Korhonen,

Salonen

et al. 2024

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses

Sinha,

Yaugel-Novoa,

Waeckel

et al. 2024

Antiviral Research

View full text Add to dashboard Cite

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

et al. 2023

View full text Add to dashboard Cite

Multiple FDA-approved SARS-CoV-2 vaccines currently provide excellent protection against severe disease. Despite this, immunity can wane relatively fast, particularly in the elderly and novel viral variants capable of evading infection- and vaccination-induced immunity continue to emerge. Intranasal (IN) vaccination more effectively induces mucosal immune responses than parenteral vaccines, which would improve protection and reduce viral transmission. Here, we developed a rationally designed IN adjuvant consisting of a combined nanoemulsion (NE)-based adjuvant and an RNA-based RIG-I agonist (IVT DI) to drive more robust, broadly protective antibody and T cell responses. We previously demonstrated this combination adjuvant (NE/IVT) potently induces protective immunity through synergistic activation of an array of innate receptors. We now demonstrate that NE/IVT with the SARS-CoV-2 receptor binding domain (RBD), induces robust and durable humoral, mucosal, and cellular immune responses of equivalent magnitude and quality in young and aged mice. This contrasted with the MF59-like intramuscular adjuvant, Addavax, which showed a decrease in immunogenicity with age. Robust antigen-specific IFN-γ/IL-2/TNF-α was induced in both young and aged NE/IVT-immunized animals, which is significant as their reduced production is associated with suboptimal protective immunity in the elderly. These findings highlight the potential of adjuvanted mucosal vaccines for improving protection against COVID-19.

show abstract

Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models

Cited by 6 publications

References 37 publications

SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays

SARS‐CoV‐2 infections among pregnant women, 2020, Finland—Cross‐testing of neutralization assays

Unmasking the potential of secretory IgA and its pivotal role in protection from respiratory viruses

Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice

Contact Info

Product

Resources

About